Key Statistics for Uterine Sarcoma
Jan 12, · Key Statistics for Soft Tissue Sarcomas The American Cancer Society's estimates for soft tissue sarcomas in the United States for are: About 13, new soft tissue sarcomas will be diagnosed (7, in males and 5, in females). About 5, people (2, males and 2, females) are expected to die of soft tissue sarcomas. An estimated 5, people (2, men and boys and 2, women and girls) are expected to die of the disease this year. Sarcomas are described as being localized, locally advanced, or metastatic when they are first found. Localized means the tumor is only in 1 area of the body.
Skip to Content. You will also how to dial conference call general information on surviving the disease. Remember, survival rates depend on several factors. Use the menu to see what does gender stereotyping mean pages. This year, xarcomas 13, people 7, men and boys and 5, women and girls will be diagnosed with STS in the United States.
An estimated 5, people 2, men ptevalence boys and 2, women and girls are expected to die of the disease this year. Sarcomas are described as being localized, locally advanced, or metastatic when they are first found.
Locally advanced means the tumor involves or attaches to nearby tissues or organs. This often means what is the prevalence of sarcomas cancer is not possible to remove the tumor because of its location, size, or the organs it involves. Metastatic means the sarcoma has spread to parts of the body far away from where the sarcoma started. This section includes information on how often sarcomas show up as localized, locally advanced, or cxncer.
In addition, there is information on survival rates for each situation. This information applies for sarcomas in prevaalence and may not apply to a specific type of sarcoma. Talk with your health care team for more what is the prevalence of sarcomas cancer regarding your specific diagnosis.
In general, cancer statistics often include the 5-year survival rate for a type of cancer. The 5-year pfevalence rate tells you what percent of people live at least 5 years after the cancer is found. Percent means how many out of It is important to note that the length of time a person lives with or sarcoma depends on many factors, including the type of sarcoma, the size, where it is located, and tge quickly the tumor cells are growing and dividing, called the how to connect ipad to monitor vga. If the sarcoma is sracomas at an early stage and has not spread from where it started, surgical treatment is often very effective and many people are cured.
However, if the sarcoma has spread to other parts of the body, treatment can oc control the tumor, but it is often incurable. Learn more in the Stages and Grades section.
It is also important to remember that statistics on the survival rates for people with STS are an estimate. The estimate comes from annual data based on the number of people with this cancer in the United States. Also, experts measure the survival statistics every 5 years.
So the estimate may not show the results of better diagnosis or treatment available for less than 5 years. Talk with your doctor if you have any questions about this information. Learn more about understanding statistics. The next section in this guide is Medical Illustrations.
What is the prevalence of sarcomas cancer offers drawings of body parts often affected by STS. Use the menu to choose a different section to read in this guide. Localized means the tumor is only in 1 area of the body. Types of Cancer. Sarcoma, Soft Tissue Guide.
Hhe Guide Sarcoma, Soft Tissue. Medical Illustrations. Risk Factors. Symptoms and Signs. Stages and Grades. Types of Treatment. About Clinical Trials. Latest Research.
Coping with Treatment. Follow-Up Care. Questions to Ask the Health Care Team. Additional Resources. View All Pages. Find a Cancer Doctor.
14 rows · SEER states that the lifetime risk for developing any cancer is 40 percent. Thus, 4 out of every. Jan 08, · Key Statistics for Uterine Sarcoma The American Cancer Society's estimates for cancer of the uterine corpus (body of the uterus) in the United States for are: About 65, new cases of cancer of the uterine corpus will be diagnosed. More than 90% . About children and teens are diagnosed with Ewing tumors (sarcomas) in the United States each year. Most Ewing tumors occur in adolescents, but they can also affect younger children, as well as adults (mainly in their 20s and 30s). Slightly more males than females develop these cancers.
Main Menu Learn About Sarcoma. What is Sarcoma? Encouraging Guidelines 2. The Sarcoma Universe 3. Sarcoma Centers 4. Sarcoma Treatment 5. Clinical Trials for Sarcoma. Sharing the Journey.
Sarcoma Research. Team Sarcoma! Please Support Sarcoma Advocacy! Editor's Note: Joan is a biologist. She is also mother of two, one of whom is an year survivor of alveolar rhabdomyosarcoma. Joan is an active volunteer for a variety of childhood cancer and sarcoma organizations and spends much of her spare time as Co-List manager of the ACOR Rhabdo-Kids mailing list, as a Patient Advocate for the Children's Oncology Group, and as a board member of the Sarcoma Alliance.
This article was inspired by several on-line postings that raised questions about the frequency of childhood cancers or sarcomas. In almost all of these postings, people seemed to understand the annual risk of developing a cancer but did not understand the cumulative risk over a lifetime. This article thus is an effort to view sarcoma statistics in a different way than they are usually presented, and possibly stimulate others to look into the interesting but not always intuitive field of cancer statistics and their uses.
Everyone who has had experience with sarcoma knows that it is an uncommon type of cancer. For example, when my daughter Ali was diagnosed with rhabdomyosarcoma rhabdo , the most common type of pediatric soft tissue sarcoma, we were told that the odds of getting this cancer were approximately six in a million.
Table 1 shows that among children under the age of 20, on average about five children out of every 1,, will be diagnosed with rhabdo each year. Add in about half of the "unspecified" cases, and that agrees closely with the six in a million incidence. Certainly it is not a common disease. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering a portion of the US population.
Click here to access the SEER glossary of statistical terms. Click here to access definitions of cancer terms by the NCI. All websites referenced in this article were accessed during the first two weeks of October, Rates are per 1,, and are age-adjusted to the US Std Population. For Kaposi's sarcoma, the number of cases was too low to calculate an incidence rate. Sarcomas are not common among any age group. In adults, sarcomas are estimated to be about one percent of all cancers, and approximately 12, people a year in the U.
Sarcomas are relatively more common among children. Between 1, and 1, U. Table 2 shows that the estimated number of new bone and soft tissue cancers most comparable to sarcomas according to the way that adult cancers are classified in the U. Worldwide Statistics : Although this article focuses on sarcomas in the U. The SEER homepage has links to international cancer registries. For additional information, see:.
Numbers such as "six in a million" are difficult for many people to understand, however. A number like this may make it seem as though only a minutely small number of families in the country are grappling with some stage of the rhabdo experience. It might be more understandable to many if incidence statistics were presented in a different way.
The incidence of many cancers is given as a lifetime risk. An oft-quoted fact about prostate cancer is that one of every 6 men will develop it sometime during their lifetime. In the same vein, one out of every 8 women will develop breast cancer during their lifetimes. It is very difficult to find comparable lifetime risks for developing sarcomas. The 1, children or 12, total numbers of sarcoma cases, and the six in a million for rhabdomyosarcoma, all represent the risk for a single year.
However, representing the risk over a lifetime rather than a single year provides two benefits in understanding the incidence of a cancer. First, it represents the actual odds of a person developing that cancer at some time during their life.
Second and perhaps as importantly, it makes the risk easier to understand. The lifetime risk is cumulative; that is, the risk of being diagnosed with a cancer in one year is added to the risk of being diagnosed in the next year, and so on. For example, each year the odds of a child getting rhabdo are about six in a million. Multiply that by the 20 years of "childhood" and the odds of a child getting rhabdo are about in a million, or just about one in 8, And since rhabdo makes up a little more than one-quarter of pediatric sarcomas, about 1 in 2, children under the age of 20 in the U.
These numbers represent the risk of a child being diagnosed with sarcoma by the age of 20 — 1 child in 8, for rhabdo, and 1 child in 2, for all sarcomas. These numbers also bring the risk into a scale that is easier to understand, as people can relate more to risks expressed in hundreds or thousands rather than those expressed in millions. The same cumulative principle holds true for adult sarcomas. There are about 12, new cases of sarcoma annually and approximately million people in the U.
Although the risk of developing a sarcoma as an adult actually varies somewhat from year to year, as a very rough estimate of lifetime risk the yearly risk can be assumed to be the same every year see "A Double Check". Multiply the annual risk by, say, 70 years of lifespan, and the odds of being diagnosed with sarcoma are 2, in a million, or about one in every people.
A Double Check : The best way to determine lifetime risk would be to use an age-adjusted formula. Unfortunately, SEER provides lifetime risks for other cancer types but not sarcomas. The number of 1 in is therefore a very rough approximation, but I believe it is a reasonable and conservative estimate.
In order to check if this figure is approximately correct, I made two other quick calculations. There is another important sarcoma statistic that underscores the impact on society rather than considering the number of cases. That statistic is the age at which sarcomas are diagnosed. Cancers that affect younger people have disproportionately large impacts, because the younger the victim, the more potential there is to contribute to society.
For example, despite the relatively small number of cases of childhood cancer, an extremely large number of years of life are lost if a child does not survive. The graphs below from SEER demonstrate this effect. The left graph in Figure 1 below illustrates that despite the rarity of childhood cancer, , person-years of life are lost each year to childhood cancer, just for children up to the age of The right graph in Figure 1 shows that for each child who does not survive cancer, 70 years of life are lost on average.
Compare this to the 9 years lost on average for prostate cancer, or the 19 years for breast cancer. Similar statistics for adult sarcomas are difficult to find since most adult cancer statistics are given by site of cancer and not by type of cancer.
As a result, sarcomas are not grouped in an easy way to analyze, but it is very likely that if adult sarcomas were broken out separately, they would also show a disproportionately large loss of person-years. The reason is that unlike many other cancers sarcoma is a disease of young and old alike. The SEER data indicates that a third of soft tissue cancers again, not exactly the same as but most comparable to soft tissue sarcomas and over half of bone sarcomas are diagnosed in people under 45 years of age.
In comparison, less than one-tenth of all cancers occur in this age group Table 3. Furthermore, the table shows that nearly half 45 percent of bone sarcomas and over a fifth 21 percent of soft tissue cancers are diagnosed in people under the age of 35 , compared to less than 4 percent of all cancers.
For four of the most common types of cancer, 0 percent of prostate cancers, less than 1 percent of lung cancers, 1 percent of colon cancers, and 2 percent of breast cancers are diagnosed in people less than Incidence of sarcomas in young people unfortunately is paralleled by deaths from sarcomas.
As can be seen in Table 4, over a third 36 percent of deaths from bone cancers and about a fifth 19 percent of deaths from soft tissue cancers occur in people under the age of 45, compared to less than 5 percent of deaths from cancers overall. The median is a type of average which represents the age at which half the people are younger at diagnosis and half are older. Assuming that most of the bone and soft tissue cancers are sarcomas, it appears that the average age of a patient diagnosed especially with a sarcoma, particularly a bone sarcoma, is considerably younger than the age of most cancer diagnoses.
The young age at which many sarcomas are diagnosed has important implications. The younger the age of diagnosis, the more years of worry about relapse or dealing with side effects of treatment. A bone sarcoma survivor diagnosed at the median age of 39 has thirty-eight more years of life to look forward to, if they live to the average U. A colon cancer survivor diagnosed at the median age of 71 would have six more years of life , on average.
Thus, research that improves sarcoma survival has a disproportionately large result if success is measured in the average number of years of life saved. Another way of measuring this impact on society is Cancer Prevalence, which is the number of people alive a certain number of years after diagnosis. SEER provides limited data for bone and soft tissue cancers, estimating that , people in the U.
Unfortunately for these cancers SEER does not provide data for complete prevalence, in other words all the people alive after a diagnosis no matter when the diagnosis was made. Survivor health issues are particularly true of children with sarcomas who required multi-modal therapy including relatively high doses of chemotherapy and radiation.
The young age at which sarcoma strikes makes research into better treatments particularly important, for at least three reasons:. Survival Statistics are also Important Pediatric sarcomas have a lower survival rate than childhood cancer overall.
Table 5 summarizes relative five-year survival rates of pediatric sarcomas for the period The average five-year survival rate for pediatric cancers is 78 percent, but for sarcomas it is considerably less.
One possible reason for lower survival rates is the fact that many sarcomas are diagnosed in adolescents and young adults in ages that fall into what has been termed the "teen gap" in treatment success see Adolescent and Young Adult Cancer Care.
The advances in cancer treatment for children and adults have not been matched for adolescents and young adults. There are several possible causes for this, including increased delay in diagnosis and lack of insurance, but one reason may be that this age group has different disease characteristics and in the past has had low enrollment in clinical trials, limiting the opportunity to improve treatments. In the past few years however there has been a concerted effort to include this group in clinical trials.
The following figure shows the average annual percent change in survival from to for all cancers and soft tissue sarcomas by age at diagnosis.
The survival rate appears to have declined for all groups from age 15 through 44, while increasing for younger and older groups.